---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-211808"
form_type: "8-K"
ticker: "AGIO"
cik: "0001439222"
company_name: "AGIOS PHARMACEUTICALS, INC."
filed_at: "2022-08-04T23:59:59+00:00"
generated_at: "2026-06-24T03:55:21.551371+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Agios Q2 2022: PYRUKYND revenue $3.1M; net loss $91.8M; CEO transition to Brian Goff

## Summary
- Q2 2022 net loss from continuing ops $91.8M vs $82.8M Q2 2021; R&D expenses rose to $74.5M.
- PYRUKYND generated $3.1M net U.S. revenue in first full quarter after Feb 2022 FDA approval.
- Cash, equivalents, marketable securities $1.1B, down from $1.7B; expects to fund to cash-flow positivity.
- Brian Goff becomes CEO Aug 8; current CEO Jackie Fouse transitions to Chair of Board.
- Five pivotal PYRUKYND studies enrolling across thalassemia, sickle cell, pediatric PK deficiency.

## SEC filing metadata
- accession: 0001193125-22-211808
- form_type: 8-K
- ticker: AGIO
- cik: 0001439222
- company_name: AGIOS PHARMACEUTICALS, INC.
- filed_at: 2022-08-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/0001193125-22-211808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1439222/000119312522211808/d389470d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-211808
- JSON: https://secwatch.observer/filing/0001193125-22-211808.json
- Plain text: https://secwatch.observer/filing/0001193125-22-211808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.